Medtronic

Medtronic
Share

Medtronic

 •  November 27

Medtronic Care Management Services Delivers on Its Commitment to Serve Veteran Patients with Expanded Suite of Telehealth Solutions
Medtronic plc (NYSE:MDT) today announced its Medtronic Care Management Services (MCMS) business commenced launch of new telehealth solutions in support of its national contract awarded by the U.S. Department of...

Medtronic

 •  November 20

Medtronic plc (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) approval and U.S. commercial launch for its portfolio of Azure(TM) pacemakers with BlueSync(TM)technology. Available in both single chamber and dual chamber models, the Azure XT MRI and Azure S MRI pacemakers offer improved longevity, estimated at 13.7 years (dual...

Medtronic

 •  November 13

Medtronic plc (NYSE: MDT) today announced several noteworthy presentations of clinical studies and symposia on aortic, peripheral, endoVenous, and vascular embolization therapies at the 44th Annual Symposium of Vascular and Endovascular Issues (VEITHsymposium), the world's largest educational meeting specializing in vascular surgical medicine in...

Medtronic

 •  November 1

First Report Investigation at TCT Published in JACC Shows Substantial Mitral Valve Regurgitation Reductions and Versatility of Dual-Stent Design
Medtronic plc (NYSE:MDT) today presented positive data for its self-expanding Intrepid(TM)transcatheter mitral valve replacement (TMVR) system in patients with severe, symptomatic mitral valve...

Medtronic

 •  October 31

Presented at TCT, Evolut TAVR Platform Showcases Positive Clinical Outcomes in Patients Wanting to Return to More Active Lives
Medtronic plc (NYSE:MDT) today presented new clinical research to support the positive clinical performance of the Evolut(TM) Transcatheter Aortic Valve Replacement (TAVR) Platform in intermediate-risk, severe,...

Medtronic

 •  October 23

Global Medtronic APOLLO Trial Now Underway with the Intrepid(TM) TMVR System for Patients with Severe Mitral Regurgitation
Medtronic plc (NYSE:MDT) today announced the first patient implant in the APOLLO Trial - the pivotal trial designed to evaluate the Intrepid(TM) TMVR system following receipt of an investigational device exemption (IDE) from...

Medtronic

 •  October 16

Medtronic plc (NYSE:MDT) today announced its Medtronic Care Management Services (MCMS) business and American Well® entered into a first-of-its-kind strategic partnership to enable a more complete telehealth solution focused on the unique needs of the complex, chronic, co-morbid patient population.
Under the terms of the agreement, the businesses...

Medtronic

 •  October 11

Facilitating Clinical Training for Physicians and Advancing Local Healthcare Efficiency in Central and Western China
Medtronic plc (NYSE:MDT) today announced the groundbreaking of its Chengdu Innovation Center at the Singapore-Sichuan Hi-Tech Innovation Park in Sichuan Province. Set to open in 2020, this center will provide a leading,...

Medtronic

 •  October 9

New Indication Expands Treatment Options for AAA Patients with Hostile Neck Anatomy
DUBLIN - October 9, 2017 - Medtronic plc (NYSE: MDT) today announced that it has received U.S. Food and Drug Administration (FDA) approval for the Endurant(TM) II/IIs stent graft system to treat abdominal aortic aneurysm (AAA) patients with neck lengths down to 4mm...

Medtronic

 •  August 2

Introduction of New Pericardial Aortic Heart Valve in the U.S. and Europe Reinforces Company's Commitment to Comprehensive Solutions to Heart Valve Disease
Medtronic plc (NYSE: MDT) today announced CE (Conformité Européenne) mark and U.S. Food and Drug Administration (FDA) approval of its new Avalus(TM) pericardial aortic surgical valve for the...